Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1590/s0104-42302007000500007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GP consultations and prescribed treatments for Raynaud's: a survey among primary Raynaud's patients in the community.
Rheumatol Adv Pract
October 2024
Scleroderma and Raynaud's UK, London, UK.
Clinical courses and predictors of left ventricular systolic dysfunction in systemic sclerosis: A cohort study.
Rheumatol Immunol Res
June 2024
Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
Background And Objectives: Left ventricular systolic dysfunction (LVSD) is a cardiac involvement that is the leading cause of death among patients with systemic sclerosis (SSc). We aimed to define the clinical course and predictors of LVSD among SSc patients.
Methods: We conducted a cohort study among adult patients with SSc who were followed up from 2013 to 2020.
Article Synopsis
- A task force of healthcare professionals created evidence-based recommendations for managing Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis and other connective tissue diseases.
- The recommendations include 5 main principles and 13 specific suggestions, with a focus on coordinated team care and shared decision-making between patients and healthcare providers.
- Nifedipine is recommended as the first-line treatment, with other medications like sildenafil and tadalafil as second-line options, while non-drug interventions are advised but lack strong evidence.
Polypharmacy, drug-drug interactions, and adverse drug reactions among systemic sclerosis patients: A cross-sectional risk factor study.
Semin Arthritis Rheum
August 2024
Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes et Autoinflammatoires Rares d'Ile de France, de l'Est et de l'Ouest, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (AP-HP); APHP-CUP, Hôpital Cochin, Université Paris Cité, F-75014, Paris. Electronic address:
Objectives: Polypharmacy, drug-drug interactions (DDI) and related adverse drug reaction (ADR) are understudied in SSc. The aim of this work was to determine the prevalence and determinants of DDI and ADR in a real-life prospective cohort of SSc patients.
Methods: We performed a retrospective analysis of the drug prescriptions of SSc patients admitted to the daily scleroderma clinic between January 2020 and April 2022.
Therapeutic management of fibrosis in systemic sclerosis patients - an analysis from the Swiss EUSTAR cohort.
Swiss Med Wkly
February 2024
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Article Synopsis
- - The study focuses on treatment patterns for systemic sclerosis patients in Switzerland, particularly those with fibrotic symptoms, using data from the EUSTAR registry.
- - A total of 590 patients were included, revealing that 71.4% had skin issues and 43.4% had interstitial lung disease, with a portion showing extensive complications.
- - The most commonly prescribed non-biologic treatments were methotrexate and hydroxychloroquine, while rituximab and tocilizumab were the leading biologic options administered to patients with skin fibrosis.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!